No Oral Formulation of Ocrelizumab Exists
There is no oral formulation of ocrelizumab (Ocrevus), which is only available as an intravenous infusion. 1 The FDA-approved formulation is administered as an IV infusion every 6 months for maintenance therapy.
Anti-CD20 Alternatives: No Oral Options Available
While you're seeking an oral medication with a similar anti-CD20 B-cell-depleting mechanism, none of the currently approved anti-CD20 monoclonal antibodies for multiple sclerosis are available in oral form:
- Ocrelizumab (Ocrevus): IV infusion only 1
- Ofatumumab: Subcutaneous injection (monthly self-administration) 2, 3
- Ublituximab: IV infusion (shorter 1-hour infusion time) 4, 5
- Rituximab: IV infusion (off-label use in MS) 2, 3
All anti-CD20 therapies work through the same fundamental mechanism—binding to CD20 on B-cells and causing B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) 1, 3.
Oral MS Therapies: Different Mechanisms
If you require an oral medication for MS, you must accept a different mechanism of action. The available oral disease-modifying therapies include 6:
- Fingolimod: Sphingosine-1-phosphate (S1P) receptor modulator
- Dimethyl fumarate (BG-12): Immunomodulatory and cytoprotective
- Teriflunomide: Dihydroorotate dehydrogenase inhibitor
- Cladribine: Purine analog (intermittent oral dosing)
Important Caveat
None of these oral agents deplete B-cells via anti-CD20 mechanisms. They reduce relapse rates by 30-60% but work through entirely different pathways than ocrelizumab 6. If the specific anti-CD20 mechanism is therapeutically necessary for your patient (e.g., highly active disease requiring maximal B-cell depletion), you cannot substitute with an oral agent.
Practical Alternatives to IV Ocrelizumab
If the goal is to avoid IV infusions rather than specifically requiring oral administration:
Ofatumumab offers subcutaneous self-injection (20 mg monthly after loading doses), which patients can administer at home 2, 3. This provides the anti-CD20 mechanism with greater convenience than IV therapy, though it requires monthly rather than biannual dosing.
Ublituximab provides shorter infusion times (1 hour vs. 2-3.5 hours for ocrelizumab) and may have lower infusion-related reaction rates due to its glycoengineered structure favoring ADCC over CDC 4, 5.
Clinical Trials Context
Recent guidelines comparing high-efficacy therapies list ocrelizumab alongside alemtuzumab, cladribine, natalizumab, and ofatumumab as comparators in ongoing MS trials 7. Notably, cladribine is the only oral option in this high-efficacy category, but it works through lymphocyte depletion, not anti-CD20 targeting.